Best Prostate Cancer Analysis Stockholm Near Me

4worldlovers: The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.

Our proprietary Salipro technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.

We are driving forward drug development in our partnered as well as internal pipelines.

New study - Salipro enables elucidation of drug interactions on a muscle nicotinic receptor using cryoEM

The Salipro platform enabled to reveal molecular interactions of muscle relaxants and anaesthetics, enhancing our understanding of their combined action and potential clinical implications.

Congratulations to Ryan Hibbs and team for solving these important cryoEM structures of muscle nicotinic receptors!

U. Goswami, et al., Structural interplay of anesthetics and paralytics on muscle nicotinic receptors. Nat. Commun. 14, 3169 (2023).

Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patent in Japan

Salipro Biotech obtains granted patent in Japan, protecting its proprietary Salipro platform technology to enable the development of therapeutics against challenging drug targets, including GPCRs, SLCs and Ion Channels.

Stockholm, Sweden, June 13, 2023 – Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, is delighted to announce the issuance of a new patent in Japan for its Salipro platform technology. The patent, entitled "Saposin lipoprotein particles and libraries from crude membranes", (Japanese Patent No. 7149929) further strengthens Salipro Biotech's leading position in the field of membrane protein research and drug discovery.

Salipro Biotech’s CSO as Keynote Speaker at Oxford Global Discovery Europe

We are excited to share that our CSO is invited as a keynote speaker at Oxford Global Discovery Europe (June 6-7) in Berlin! Join us on June 6th as Robin Löving takes the stage to discuss drug discovery against challenging drug targets, such as GPCRs, ion channels and transporters.